Health · Pharma & Biotech · 1 day ago
Boston Scientific launches FARAPOINT catheter in mainland China
Boston Scientific launched its FARAPOINT catheter in mainland China during the China International Import Expo in Shanghai.
It is intended for linear ablation in certain patients with persistent atrial fibrillation whose symptoms do not respond to medication.
Atrial fibrillation is an irregular heart rhythm, and catheter ablation uses energy to create areas of tissue that help control the rhythm.
FARAPOINT uses pulsed electric fields and is designed to make lines of treated tissue between the inferior vena cava and the tricuspid valve.
It adds a linear-ablation tool to the company's FARAPULSE platform, alongside catheters used for larger treatment areas such as pulmonary vein isolation.
The platform has been used for more than 20,000 patients in mainland China, according to the company.
In a clinical study, FARAPOINT ablation took about five minutes, and 97.9% of patients were free of typical atrial flutter recurrence at 360 days; the company says it will continue working with Chinese clinicians to support use and training.
Boston Scientific launched its FARAPOINT pulse-field ablation catheter in mainland China on November 7.
The catheter is designed for linear ablation and expands the company’s FARAPULSE platform.
It is intended for use with specified equipment to treat drug-refractory, symptomatic persistent atrial fibrillation.
Boston Scientific said the FARAPULSE platform had been used to treat more than 20,000 patients in mainland China.
The launch was announced during the ninth China International Import Expo in Shanghai.
- Who
- Boston Scientific.
- What
- It launched the FARAPOINT pulse-field ablation catheter in mainland China.
- When
- November 7, 2026.
- Where
- Shanghai, during the ninth China International Import Expo.
- Why
- The catheter adds a tool for linear ablation to the FARAPULSE platform and is intended to treat drug-refractory, symptomatic persistent atrial fibrillation.
This story does not have two clearly opposing sides.
The FARAWAVE pulse-field ablation catheter was approved for sale in China.
FARAPULSE had been used in more than 500,000 procedures globally, according to the article.
The FARAWAVE NAV was introduced in China.
Boston Scientific announced FARAPOINT’s launch in mainland China at the China International Import Expo in Shanghai.
- Catheter
- FARAPOINT
- Launch date
- November 7, 2026
- Launch location
- Shanghai, China
- China platform use
- More than 20,000 patients
- Intended ablation target
- Linear ablation between the inferior vena cava and tricuspid valve
- Registration certificate
- 国械注进2026301037
What people are saying
FARAPOINT’s launch in China is an important step in our continued efforts to improve our atrial fibrillation solutions.
We believe leadership in the PFA field is reflected not only in technological innovation, but also in whether innovation can truly serve clinical needs through solid clinical evidence and ongoing professional support.